Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Trypanosoma brucei | ATP-dependent 6-phosphofructokinase, glycosomal | Starlite/ChEMBL | No references |
Trypanosoma brucei gambiense | ATP-dependent phosphofructokinase,6-phospho-1-fructokinase | No references | |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | fatty acid amide hydrolase 1 | 0.0101 | 0.6811 | 0.6469 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0069 | 0.3492 | 0.3492 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0069 | 0.3492 | 0.3492 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0045 | 0.0971 | 0.04 |
Brugia malayi | amidase | 0.0101 | 0.6811 | 0.661 |
Trichomonas vaginalis | valacyclovir hydrolase, putative | 0.0069 | 0.3492 | 0.3492 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0045 | 0.0971 | 0.04 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.2582 | 0.2114 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0045 | 0.0971 | 0.04 |
Loa Loa (eye worm) | hypothetical protein | 0.0101 | 0.6811 | 0.661 |
Plasmodium vivax | PST-A protein | 0.0069 | 0.3492 | 1 |
Echinococcus granulosus | fatty acid amide hydrolase 1 | 0.0101 | 0.6811 | 0.6469 |
Schistosoma mansoni | CREB-binding protein 2 | 0.0088 | 0.5468 | 0.5182 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.2582 | 0.2114 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0069 | 0.3492 | 0.3492 |
Loa Loa (eye worm) | CBP-B | 0.0088 | 0.5468 | 0.5182 |
Entamoeba histolytica | hydrolase, alpha/beta fold family domain containing protein | 0.0069 | 0.3492 | 0.3492 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0069 | 0.3492 | 0.3492 |
Schistosoma mansoni | CREB-binding protein 1 (SmCBP1) | 0.0088 | 0.5468 | 0.5182 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.2582 | 0.2114 |
Plasmodium falciparum | lysophospholipase, putative | 0.0069 | 0.3492 | 1 |
Plasmodium falciparum | lysophospholipase, putative | 0.0069 | 0.3492 | 1 |
Schistosoma mansoni | fatty-acid amide hydrolase | 0.0101 | 0.6811 | 0.661 |
Echinococcus multilocularis | CREB binding protein | 0.0088 | 0.5468 | 0.498 |
Echinococcus granulosus | CREB binding protein | 0.0088 | 0.5468 | 0.498 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0045 | 0.0971 | 0.04 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0069 | 0.3492 | 0.3492 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0069 | 0.3492 | 0.3492 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0045 | 0.0971 | 0.04 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0069 | 0.3492 | 0.3492 |
Entamoeba histolytica | hydrolase, alpha/beta fold family domain containing protein | 0.0069 | 0.3492 | 0.3492 |
Echinococcus granulosus | CREB binding protein | 0.0088 | 0.5468 | 0.498 |
Brugia malayi | TAZ zinc finger family protein | 0.0088 | 0.5468 | 0.5182 |
Echinococcus multilocularis | fatty acid amide hydrolase 1 | 0.0101 | 0.6811 | 0.6469 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.2582 | 0.2114 |
Plasmodium falciparum | esterase, putative | 0.0069 | 0.3492 | 1 |
Echinococcus granulosus | fatty acid amide hydrolase 1 | 0.0101 | 0.6811 | 0.6469 |
Schistosoma mansoni | amidase | 0.0101 | 0.6811 | 0.661 |
Plasmodium falciparum | lysophospholipase, putative | 0.0069 | 0.3492 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.8492 uM | PUBCHEM_BIOASSAY: qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488768, AID492961] | ChEMBL. | No reference |
Potency (functional) | 14.1254 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.9185 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (binding) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.